within Pharmacolibrary.Drugs.ATC.L;

model L01ED01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.43,
    Cl             = 60.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,
    adminCount     = 1,
    Vd             = 1.21,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007899999999999999,
    Tlag           = 13.98
  );

  annotation(Documentation(
    info ="<html><body><p>Crizotinib is an orally administered small-molecule inhibitor of ALK (anaplastic lymphoma kinase), ROS1, and MET tyrosine kinases used for the treatment of ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC). It is approved for use in adults with advanced or metastatic NSCLC.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients, oral administration, typical dose 250 mg twice daily, analyzed as a two-compartment model with first-order absorption.</p><h4>References</h4><ol><li><p>Shaw, AT, et al., &amp; Iafrate, AJ (2014). Crizotinib in ROS1-rearranged non-small-cell lung cancer. <i>The New England journal of medicine</i> 371(21) 1963–1971. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1406766&quot;>10.1056/NEJMoa1406766</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25264305/&quot;>https://pubmed.ncbi.nlm.nih.gov/25264305</a></p></li><li><p>Johnson, TR, et al., &amp; Smith, BJ (2015). Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 45(1) 45–59. DOI:<a href=&quot;https://doi.org/10.3109/00498254.2014.941964&quot;>10.3109/00498254.2014.941964</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25034009/&quot;>https://pubmed.ncbi.nlm.nih.gov/25034009</a></p></li><li><p>Xu, H, et al., &amp; Bello, A (2015). Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects. <i>Journal of clinical pharmacology</i> 55(1) 104–113. DOI:<a href=&quot;https://doi.org/10.1002/jcph.356&quot;>10.1002/jcph.356</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24990113/&quot;>https://pubmed.ncbi.nlm.nih.gov/24990113</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01ED01;
